Heart Dysfunction, Hypertension and Pulmonary

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

DAIC

FEBRUARY 27, 2024

milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St.

Pulmonary

Pulmonary Hypertension Heart Failure Blood Pressure

Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement

Open Heart

OCTOBER 19, 2022

Moreover, pulmonary artery pressures were ameliorated (estimated systolic pulmonary artery pressure: from 47.2±15.8 However, right heart dysfunction as well as the proportion of patients with severe tricuspid regurgitation remained unchanged. ±15.8 ±15.1 mm Hg, p value: 0.0079). to 94.8%)).

Aortic valve

Aortic valve Aortic Stenosis TAVR

Trying to answer two casual queries on RV dysfunction

Dr. S. Venkatesan MD

AUGUST 3, 2024

However, It is surprising even in chronic pulmonary hypertension , the degree of RVH is not constant and homogenous.This is because , different parts of RV chamber has different wall thickness.Further, the pressure distribution from PA to RV is uneven. Eur J Heart Fail 2016; 18: 226

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Heart Dysfunction

Cardiovascular Update

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement

Trying to answer two casual queries on RV dysfunction

Stay Connected